Tiziana Life Sciences' Foralumab intranasal anti-CD3 targets the Treg–microglia axis. However, their intranasal delivery makes them unique and patient-friendly. Foralumab has a Phase 2 for SPMS, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback